Wetherby, United Kingdom

Avacta is a UK-based biopharmaceutical company developing novel cancer immunotherapeutics and high performing diagnostics, based on its two proprietary platforms: Affimer and pre|CISION.


Investment Perspective

Avacta is a UK-based diagnostic and nascent clinical stage drug development company. Much investor attention has focused on the near-term commercial opportunities for its point-of-care COVID-19 LFT (lateral flow test). Attractive as these prospects are, we argue greater long-term value lies within the Therapeutics pipeline. The first programme from the two proprietary platforms, Affimer and pre|CISION, is set to enter human trials. Successful clinical results would validate the concept and support a material broadening of the pipeline. Ample news flow is expected over 18-24 months, providing multiple value-inflection points. Our valuation is £710m, equivalent to 280p/share.

Market information

SymbolPrimary exchanges


AVA6000 set to start US Phase I studies in early-2022
Lighthouse | 29 Nov 2021
Foundations for two healthy businesses now in place
Lighthouse | 30 Sep 2021
Lead therapeutic asset AVA6000 enters the clinic
Lighthouse | 11 Aug 2021

Recent News

IND clearance for AVA6000
29 Nov 2021
Interim H121 results
30 Sep 2021
Development milestone in LG Chem partnership
29 Sep 2021
Appointment of CSO
02 Sep 2021